Redhill Biopharma Ltd. (NASDAQ:RDHL) is set to announce third quarter earning results on Thursday 12th November 2020, before market open.
Analysts surveyed by Thomson Reuters are predicting, RDHL to report 3Q20 loss of $ 0.16 per share.
For the full year, analysts anticipate top line of $ 82.55 million, while looking forward to loss of $ 0.66 per share bottom line.
Previous Quarter Performance
Redhill Biopharma Ltd. communicated income for the second quarter of $ 0.04 per share, from the revenue of $ 20.90 million. The quarterly revenues swell 1,392.86 percent compared with the same quarter last year. Street analysts expected Redhill Biopharma Ltd. to report loss of $ 0.06 per share on revenue of $ 27.32 million for the second quarter. The bottom line results beat street analysts by $ 0.1 or 166.67 percent, at the same time, top line results fell short of analysts by $ 6.42 million or 23.5 percent.
Stock Performance
Shares of Redhill Biopharma Ltd. traded up $ 0.02 or 0.24 percent on Wednesday, reaching $ 8.22 with volume of 150.90 thousand shares. Redhill Biopharma Ltd. has traded high as $ 8.38 and has cracked $ 8.11 on the downward trend
The closing price of $ 8.22, representing a 151.53 % increase from the 52 week low of $ 3.26 and a 27.75 % decrease over the 52 week high of $ 11.35.
The company has a market capital of $ 307.50 million and is part of the Healthcare sector and Biotechnology industry.
Conference Call
Redhill Biopharma Ltd. will be hosting a conference call at 8:30 AM eastern time on 12th November 2020, to discuss its 3Q20 financial results with the investment community. The participants may dial, +1-877-870-9135 U.S. or +1-646-741-3167 Outside U.S., when prompted, enter passcode 4549918 in order to access the live audio call. A live webcast with presentations will be available on the Internet by visiting the Company website www.redhillbio.com
RedHill Biopharma Ltd., a specialty biopharmaceutical company, focuses on the development and commercialization of late clinical-stage drugs for the treatment of gastrointestinal diseases in the United States. It operates through two segments, Commercial Operations and Research & Development. The companys clinical-stage development programs comprise TALICIA, a drug that is in Phase III clinical trial for the helicobacter pylori infection; RHB-104 that is in Phase III clinical trials for crohns disease, as well as that has completed Phase II clinical trial for multiple sclerosis; RHB-204 for pulmonary nontuberculous mycobacteria infections; BEKINDA 24 mg that has completed Phase III clinical trial for acute gastroenteritis and gastritis; BEKINDA 12 mg that has completed Phase II clinical trial for irritable bowel syndrome with diarrhea; RHB-106 for bowel preparation; and RHB-107 that has completed Phase II clinical trial for gastrointestinal and other solid tumors.
